- ONL Therapeutics, Inc., an Ann Arbor, Mich.-based biopharmaceutical company, closed on $46.9m in a Series B financing round
- This funding supports the completion of a Phase 1 study in retinal detachment with ONL’s lead compound ONL1204
- In addition, the capital will advance ONL1204 in two chronic indications, glaucoma and dry age-related macular degeneration
- ONL Therapeutics is a biopharmaceutical company committed to protecting and improving the vision of patients with retinal disease
- ONL also developing a platform of products for use in a wide range of blinding diseases, including retinal detachment, glaucoma, AMD, and IRD
- ONL1204 is a novel, small-molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors
